Andreas Wallnöefer has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Executive Leadership team and nearly a decade as a board member in several biotech companies. He has been a Partner at the Swiss venture capital firm BioMedPartners and later at Jeito Capital, a leading European investment company based in Paris.
An accomplished investor, board member and operator, Andreas has played a pivotal role in developing many innovative companies, contributing to several successful exits, including the recent acquisition of EyeBio by MSD—a deal valued in total at US $3 billion, achieved only 3 years after the company’s inception. Prior to his career in venture capital, Andreas held several Executive R&D roles at Roche including Global Head of Clinical Research and Development. His team was in charge of the R&D diligence of all Roche licensing and acquisitions during that time, including several breakthrough medicines and commercial blockbusters.
Andreas holds a Ph.D. in Pharmacology from the University of Basel, degrees in Pharmaceutical Medicine, and was trained as a Clinical Research fellow at the Centre of Human Drug Research at the University Hospital of Leiden, Netherlands. He also holds an Executive M.B.A. from IMD Lausanne.
